FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809822135> ?p ?o ?g. }

• W2809822135 endingPage "S262" @default.
• W2809822135 startingPage "S262" @default.
• W2809822135 abstract "Management of Hemophilia B requires intravenous factor IX (FIX) infusions to replenish missing coagulation factor. The introduction of extended half-life (EHL) replacement products in the US, with longer half-lives compared to standard half-life (SHL) product enabled comparison of expenditures and dispensation of clotting factor concentrates for the treatment of Hemophilia B with two EHL products versus an SHL product. De-identified claims from a large national specialty pharmacy claims database were used to identify male patients with severe or moderate hemophilia B who received FIX replacement from Apr 2015 (month first EHL FIX dispensed) to Sep 2017 and had data for at least 1 month of dispensation. SHL vs EHL groups were compared. Key outcome measures were direct expenditures and factor IUs dispensed. Expenditures and IUs dispensed were measured over monthly increments. Descriptive statistics were used to analyze results. Medians for expenditures and IUs were used to accommodate for the skewness of data distribution. 386 Hemophilia B patients met the inclusion criteria and were included in the analysis. The SHL group comprised of 293 nonacog alfa patients and the EHL group included 107 eftrenonacog alfa patients and 45 albutrepenonacog alfa patients. The albutrepenonacog group had a proportionately higher number of pediatric patients. The median FIX product dispensation per patient per calendar month was 16,134 IU (IQR, 26,903 IU) (nonacog) versus 16,380 IU (IQR, 17,287 IU) (eftrenonacog) and 10,039 IU (IQR, 10,620 IU) (albutrepenonacog). Median expenditures per patient per calendar month were higher for EHLs (eftrenonacog $48,336; IQR, $49,970; and albutrepenonacog $42,664; IQR, $45,135) than for SHL ($21,849; IQR, $36,102). This real-world data analysis, unadjusted for treatment regimen, showed higher expenditure among U.S. moderate/severe hemophilia B patients who used EHL, compared to SHL FIX. Further analyses, incorporating essential clinical characteristics and drug regimen, should be explored." @default.
• W2809822135 created "2018-07-10" @default.
• W2809822135 creator A5009150921 @default.
• W2809822135 creator A5013714336 @default.
• W2809822135 creator A5032601261 @default.
• W2809822135 creator A5045879639 @default.
• W2809822135 creator A5054448346 @default.
• W2809822135 creator A5065318301 @default.
• W2809822135 creator A5076423884 @default.
• W2809822135 date "2018-05-01" @default.
• W2809822135 modified "2023-09-26" @default.
• W2809822135 title "Real World Data Analysis of US Claims Database on Coagulation Factor IX Expenditures in Patients with Hemophilia B: Standard half-Life Vs. Extended Half-Life Products" @default.
• W2809822135 doi "https://doi.org/10.1016/j.jval.2018.04.1752" @default.
• W2809822135 hasPublicationYear "2018" @default.
• W2809822135 type Work @default.
• W2809822135 sameAs 2809822135 @default.
• W2809822135 citedByCount "1" @default.
• W2809822135 countsByYear W28098221352022 @default.
• W2809822135 crossrefType "journal-article" @default.
• W2809822135 hasAuthorship W2809822135A5009150921 @default.
• W2809822135 hasAuthorship W2809822135A5013714336 @default.
• W2809822135 hasAuthorship W2809822135A5032601261 @default.
• W2809822135 hasAuthorship W2809822135A5045879639 @default.
• W2809822135 hasAuthorship W2809822135A5054448346 @default.
• W2809822135 hasAuthorship W2809822135A5065318301 @default.
• W2809822135 hasAuthorship W2809822135A5076423884 @default.
• W2809822135 hasBestOaLocation W28098221351 @default.
• W2809822135 hasConcept C126322002 @default.
• W2809822135 hasConcept C187212893 @default.
• W2809822135 hasConcept C2781221834 @default.
• W2809822135 hasConcept C41008148 @default.
• W2809822135 hasConcept C71924100 @default.
• W2809822135 hasConcept C77088390 @default.
• W2809822135 hasConceptScore W2809822135C126322002 @default.
• W2809822135 hasConceptScore W2809822135C187212893 @default.
• W2809822135 hasConceptScore W2809822135C2781221834 @default.
• W2809822135 hasConceptScore W2809822135C41008148 @default.
• W2809822135 hasConceptScore W2809822135C71924100 @default.
• W2809822135 hasConceptScore W2809822135C77088390 @default.
• W2809822135 hasLocation W28098221351 @default.
• W2809822135 hasOpenAccess W2809822135 @default.
• W2809822135 hasPrimaryLocation W28098221351 @default.
• W2809822135 hasRelatedWork W1995515455 @default.
• W2809822135 hasRelatedWork W2039318446 @default.
• W2809822135 hasRelatedWork W2080531066 @default.
• W2809822135 hasRelatedWork W2092376035 @default.
• W2809822135 hasRelatedWork W2410491650 @default.
• W2809822135 hasRelatedWork W2604682584 @default.
• W2809822135 hasRelatedWork W2748952813 @default.
• W2809822135 hasRelatedWork W2899084033 @default.
• W2809822135 hasRelatedWork W3032375762 @default.
• W2809822135 hasRelatedWork W3108674512 @default.
• W2809822135 hasVolume "21" @default.
• W2809822135 isParatext "false" @default.
• W2809822135 isRetracted "false" @default.
• W2809822135 magId "2809822135" @default.
• W2809822135 workType "article" @default.